COST-UTILITY ANALYSIS OF ADALIMUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS IN PATIENTS IN SPAIN

被引：0
|
作者：
Wang, S. [1 ]
Yang, H. [2 ]
Yang, M. [2 ]
Bao, Y. [1 ]
机构：
[1] AbbVie Inc, N Chicago, IL USA
[2] Anal Grp Inc, Boston, MA USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2452
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY68
引用
收藏
页码：A670 / A670
页数：1
相关论文
共 50 条
  • [1] Cost-utility analysis of Amevive™ (alefacept) in the treatment of patients with moderate-to-severe psoriasis
    Iskedjian, M
    Barkovsky, L
    Desjardins, O
    Walker, JH
    Dorkalam, M
    Shear, N
    Einarson, TR
    [J]. VALUE IN HEALTH, 2005, 8 (03) : 331 - 331
  • [2] Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
    Xie F.
    Blackhouse G.
    Assasi N.
    Gaebel K.
    Robertson D.
    Goeree R.
    [J]. Cost Effectiveness and Resource Allocation, 7 (1)
  • [3] A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy
    Colombo, Giorgio L.
    Di Matteo, Sergio
    Peris, Ketty
    Fargnoli, Maria Concetta
    Esposito, Maria
    Mazzotta, Annamaria
    Chimenti, Sergio
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2009, 1 : 53 - 59
  • [4] A COST-UTILITY ANALYSIS OF ETANERCEPT FOR THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS IN ITALY
    Di Matteo, S.
    Colombo, G. L.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A457 - A457
  • [5] Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
    Sands, Bruce E.
    Peyrin-Biroulet, Laurent
    Loftus, Edward V., Jr.
    Danese, Silvio
    Colombel, Jean-Frederic
    Toruner, Murat
    Jonaitis, Laimas
    Abhyankar, Brihad
    Chen, Jingjing
    Rogers, Raquel
    Lirio, Richard A.
    Bornstein, Jeffrey D.
    Schreiber, Stefan
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (13): : 1215 - 1226
  • [6] COST-UTILITY ANALYSIS OF APREMILAST FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN SPAIN
    Carrascosa, J. M.
    Vanaclocha, F.
    Caloto, T.
    Echave, M.
    Oyaguez, I
    Tencer, T.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A420 - A420
  • [7] Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis
    Tribich, Samuel
    Maurice, James
    [J]. FRONTLINE GASTROENTEROLOGY, 2020, 11 (02) : 173 - 173
  • [8] Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
    O'Connor, Donal B.
    Lahiff, Conor
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01): : 92 - 93
  • [9] A critical review of adalimumab for the treatment of moderate-to-severe active ulcerative colitis in children
    Pigneur, Benedicte
    Ruemmele, Frank M.
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (11-12) : 1023 - 1028
  • [10] Cost-Utility Analysis Shows Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis
    Beilman, Candace L.
    Thanh Nguyen
    Ung, Victoria
    Ma, Christopher
    Wong, Karen
    Kroeker, Karen
    Lee, Thomas
    Wang, Haili
    Ohinmaa, Arto
    Jacobs, Phil
    Halloran, Brendan P.
    Fedorak, Richard N.
    [J]. GASTROENTEROLOGY, 2016, 150 (04) : S631 - S632
12345